Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

AbbVie Inc. (NYSE:ABBV)

Common Stock Valuation Ratios (Price Multiples)

Beginner level

Current Valuation Ratios

AbbVie Inc., current price multiples

Microsoft Excel LibreOffice Calc
AbbVie Inc. Abbott Laboratories Amgen Inc. Bristol-Myers Squibb Co. Eli Lilly & Co. Gilead Sciences Inc. Illumina Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. Zoetis Inc. Pharmaceuticals & Biotechnology Health Care
Selected Financial Data
Current share price (P) $110.52
No. shares of common stock outstanding 1,765,473,923
Growth rate (g) 25.19%
 
Earnings per share (EPS) $4.46
Next year expected EPS $5.59
Operating profit per share $7.35
Sales per share $18.84
Book value per share (BVPS) $-4.63
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 24.76 53.50 18.22 43.72 21.94 14.74 54.84 27.91 21.43 12.54 26.12 49.84 51.19 24.29 27.34
Price to next year expected earnings 19.77 55.70 16.00 45.60 19.05 11.64 44.39 33.63 22.18 11.91 21.46 45.37 36.56 22.22 24.98
Price-earnings-growth (PEG) 0.98 1.31 1.45 0.55 2.33 2.38 1.20 5.07 1.28 2.61 2.89
Price to operating profit (P/OP) 15.03 43.53 14.77 25.43 36.69 18.52 55.78 21.30 18.18 15.48 25.01 48.98 39.04 21.76 23.99
Price to sales (P/S) 5.87 6.18 6.44 5.75 8.18 3.59 15.51 5.14 4.50 3.94 7.03 14.09 12.27 5.63 4.48

Based on: 10-K (filing date: 2020-02-21).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

AbbVie Inc., historical price multiples

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Price to earnings (P/E) 17.82 20.60 35.47 16.54 17.01
Price to operating profit (P/OP) 10.82 18.35 19.63 10.49 11.61
Price to sales (P/S) 4.22 3.58 6.67 3.84 3.83
Price to book value (P/BV) 36.95 21.24 22.17

Based on: 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. AbbVie Inc.’s P/E ratio decreased from 2017 to 2018 and from 2018 to 2019.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. AbbVie Inc.’s P/OP ratio decreased from 2017 to 2018 and from 2018 to 2019.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. AbbVie Inc.’s P/S ratio decreased from 2017 to 2018 but then slightly increased from 2018 to 2019.

Price to Earnings (P/E)

AbbVie Inc., historical P/E calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 1,479,156,683 1,475,083,514 1,587,972,655 1,593,920,285 1,611,238,226
Selected Financial Data (US$)
Net earnings (in millions) 7,882  5,687  5,309  5,953  5,144 
Earnings per share (EPS)2 5.33 3.86 3.34 3.73 3.19
Share price1, 3 94.96 79.41 118.60 61.77 54.29
Valuation Ratio
P/E ratio4 17.82 20.60 35.47 16.54 17.01
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 41.83 56.47 220.29 55.16 12.83
Amgen Inc. 17.07 14.01 64.06 16.03 15.95
Bristol-Myers Squibb Co. 41.99 16.81 103.55 20.56 64.22
Eli Lilly & Co. 16.19 39.13 32.39 33.35
Gilead Sciences Inc. 16.45 15.26 22.75 6.83 6.75
Illumina Inc. 43.43 52.00 44.63 52.01 50.07
Johnson & Johnson 25.99 23.74 268.10 20.08 18.80
Merck & Co. Inc. 20.60 33.46 61.63 46.14 31.64
Pfizer Inc. 11.63 21.58 9.99 28.10 26.37
Regeneron Pharmaceuticals Inc. 19.86 18.17 28.99 42.64 60.50
Vertex Pharmaceuticals Inc. 52.90 22.59 155.08
Zoetis Inc. 45.89 28.68 44.09 31.63 62.14
P/E Ratio, Sector
Pharmaceuticals & Biotechnology 21.51 23.71 38.05 21.33 19.24
P/E Ratio, Industry
Health Care 23.31 25.51 35.65 22.95 20.83

Based on: 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19).

1 Data adjusted for splits and stock dividends.

2 2019 Calculation
EPS = Net earnings ÷ No. shares of common stock outstanding
= 7,882,000,000 ÷ 1,479,156,683 = 5.33

3 Closing price as at the filing date of AbbVie Inc.’s Annual Report.

4 2019 Calculation
P/E ratio = Share price ÷ EPS
= 94.96 ÷ 5.33 = 17.82

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. AbbVie Inc.’s P/E ratio decreased from 2017 to 2018 and from 2018 to 2019.

Price to Operating Profit (P/OP)

AbbVie Inc., historical P/OP calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 1,479,156,683 1,475,083,514 1,587,972,655 1,593,920,285 1,611,238,226
Selected Financial Data (US$)
Operating earnings (in millions) 12,983  6,383  9,592  9,384  7,537 
Operating profit per share2 8.78 4.33 6.04 5.89 4.68
Share price1, 3 94.96 79.41 118.60 61.77 54.29
Valuation Ratio
P/OP ratio4 10.82 18.35 19.63 10.49 11.61
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 34.03 36.64 60.88 24.25 19.80
Amgen Inc. 13.84 11.46 12.71 12.64 13.07
Bristol-Myers Squibb Co. 24.42 16.16 28.87 19.79 53.18
Eli Lilly & Co. 27.08 33.99 39.61 25.63 29.86
Gilead Sciences Inc. 20.66 10.15 7.45 5.23 5.50
Illumina Inc. 44.17 48.64 53.47 40.99 37.71
Johnson & Johnson 19.83 18.34 18.94 16.09 16.50
Merck & Co. Inc. 17.47 25.08 22.58 33.62 20.29
Pfizer Inc. 14.36 17.19 15.62 16.88 15.52
Regeneron Pharmaceuticals Inc. 19.01 17.53 16.71 28.70 30.74
Vertex Pharmaceuticals Inc. 51.98 74.57 331.55 2,143.58
Zoetis Inc. 35.00 22.59 22.33 18.65 28.09
P/OP Ratio, Sector
Pharmaceuticals & Biotechnology 19.27 19.33 18.63 15.62 15.16
P/OP Ratio, Industry
Health Care 20.45 20.05 19.32 16.43 15.92

Based on: 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19).

1 Data adjusted for splits and stock dividends.

2 2019 Calculation
Operating profit per share = Operating earnings ÷ No. shares of common stock outstanding
= 12,983,000,000 ÷ 1,479,156,683 = 8.78

3 Closing price as at the filing date of AbbVie Inc.’s Annual Report.

4 2019 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 94.96 ÷ 8.78 = 10.82

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. AbbVie Inc.’s P/OP ratio decreased from 2017 to 2018 and from 2018 to 2019.

Price to Sales (P/S)

AbbVie Inc., historical P/S calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 1,479,156,683 1,475,083,514 1,587,972,655 1,593,920,285 1,611,238,226
Selected Financial Data (US$)
Net revenues (in millions) 33,266  32,753  28,216  25,638  22,859 
Sales per share2 22.49 22.20 17.77 16.08 14.19
Share price1, 3 94.96 79.41 118.60 61.77 54.29
Valuation Ratio
P/S ratio4 4.22 3.58 6.67 3.84 3.83
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.83 4.37 3.84 3.70 2.78
Amgen Inc. 6.03 5.22 5.82 5.65 5.28
Bristol-Myers Squibb Co. 5.52 3.67 5.02 4.72 6.07
Eli Lilly & Co. 6.03 5.15 3.71 4.18 4.02
Gilead Sciences Inc. 4.00 3.84 4.10 3.08 3.80
Illumina Inc. 12.28 12.89 11.77 10.03 10.41
Johnson & Johnson 4.79 4.45 4.56 4.62 4.13
Merck & Co. Inc. 4.33 4.92 3.68 4.54 3.56
Pfizer Inc. 3.66 4.49 4.05 3.84 3.76
Regeneron Pharmaceuticals Inc. 5.34 6.62 5.92 7.86 9.38
Vertex Pharmaceuticals Inc. 14.95 15.54 16.42 12.51 20.38
Zoetis Inc. 11.00 7.03 7.18 5.31 4.42
P/S Ratio, Sector
Pharmaceuticals & Biotechnology 4.99 4.70 4.72 4.40 4.20
P/S Ratio, Industry
Health Care 3.82 3.57 3.55 3.23 3.15

Based on: 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19).

1 Data adjusted for splits and stock dividends.

2 2019 Calculation
Sales per share = Net revenues ÷ No. shares of common stock outstanding
= 33,266,000,000 ÷ 1,479,156,683 = 22.49

3 Closing price as at the filing date of AbbVie Inc.’s Annual Report.

4 2019 Calculation
P/S ratio = Share price ÷ Sales per share
= 94.96 ÷ 22.49 = 4.22

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. AbbVie Inc.’s P/S ratio decreased from 2017 to 2018 but then slightly increased from 2018 to 2019.

Price to Book Value (P/BV)

AbbVie Inc., historical P/BV calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1 1,479,156,683 1,475,083,514 1,587,972,655 1,593,920,285 1,611,238,226
Selected Financial Data (US$)
Stockholders’ equity (deficit) (in millions) (8,172) (8,446) 5,097  4,636  3,945 
Book value per share (BVPS)2 -5.52 -5.73 3.21 2.91 2.45
Share price1, 3 94.96 79.41 118.60 61.77 54.29
Valuation Ratio
P/BV ratio4 36.95 21.24 22.17
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 4.96 4.38 3.40 3.76 2.68
Amgen Inc. 13.84 9.41 5.02 4.14 3.94
Bristol-Myers Squibb Co. 2.80 5.89 8.88 5.66 7.04
Eli Lilly & Co. 51.67 12.87 7.33 6.33 5.51
Gilead Sciences Inc. 3.93 3.89 5.15 4.88 6.59
Illumina Inc. 9.43 11.43 11.79 10.95 12.50
Johnson & Johnson 6.61 6.08 5.79 4.72 4.07
Merck & Co. Inc. 7.83 7.79 4.30 4.51 3.15
Pfizer Inc. 3.00 3.80 2.98 3.40 2.84
Regeneron Pharmaceuticals Inc. 3.79 5.07 5.66 8.58 10.53
Vertex Pharmaceuticals Inc. 10.23 10.68 20.14 18.42 22.38
Zoetis Inc. 25.42 18.74 21.52 17.46 19.72
P/BV Ratio, Sector
Pharmaceuticals & Biotechnology 6.37 6.63 5.54 4.93 4.42
P/BV Ratio, Industry
Health Care 5.44 5.42 4.84 4.32 3.85

Based on: 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-27), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17), 10-K (filing date: 2016-02-19).

1 Data adjusted for splits and stock dividends.

2 2019 Calculation
BVPS = Stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= -8,172,000,000 ÷ 1,479,156,683 = -5.52

3 Closing price as at the filing date of AbbVie Inc.’s Annual Report.

4 2019 Calculation
P/BV ratio = Share price ÷ BVPS
= 94.96 ÷ -5.52 =

5 Click competitor name to see calculations.